Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Argus Health
Federal Trade Commission
Deloitte
McKinsey
Queensland Health
US Army
QuintilesIMS
Johnson and Johnson

Generated: May 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,760,090

« Back to Dashboard

Summary for Patent: 5,760,090
Title: Method for treating asthma using optically pure R(-) albuterol
Abstract:The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.
Inventor(s): Barberich; Timothy J. (Concord, MA), Young; James W. (Still River, MA)
Assignee: Sepracor, Inc. (Marlborough, MA)
Application Number:08/691,604
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,760,090
Patent Claims: 1. A method of treating asthma, while reducing side effects associated with the administration of racemic albuterol, comprising administering to an individual suffering from asthma a quantity of an optically pure R(-) isomer of albuterol sufficient to result in bronchodilation while simultaneously reducing undesirable side effects, said R isomer being substantially free of its S(+) isomer.

2. A method according to claim 1, wherein the albuterol comprises at least 90% by weight of the R(-) isomer and not more than 10% by weight of the S(+) isomer.

3. A method according to claim 1, wherein the albuterol comprises at least 99% by weight of the R(-) isomer and 1% or less by weight of the S(+) isomer.

4. A method according to claim 1, wherein the optically pure R(-) albuterol is administered by inhalation.

5. A method according to claim 4, wherein the optically pure R(-) albuterol is administered in an amount of about 30 .mu.g to about 90 .mu.g.

6. A method according to claim 1, wherein the optically pure R(-) albuterol is administered orally.

7. A method according to claim 6, wherein the optically pure R(-) albuterol is administered in an amount of about 1 mg to about 8 mg.

8. A method according to claim 6, wherein the optically pure R(-) albuterol is administered as a syrup.

9. A method according to claim 7, wherein the optically pure R(-) albuterol is administered as a syrup.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
UBS
Baxter
McKinsey
Fuji
Medtronic
Chinese Patent Office
Accenture
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.